Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
Cosmos Health (NASDAQ:COSM) has signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplements in Oman. The deal includes an initial purchase order of 42,000 units and marks COSM's strategic entry into the GCC nutraceuticals market, valued at $6.91 billion in 2024.
Scientific Pharmacy, owned by Gulf Pharmaceutical Industries (Julphar), will manage regulatory compliance, product registration, distribution, marketing, and retail sales through its established network. The GCC nutraceuticals market is projected to reach $15.5 billion by 2033, growing at a CAGR of 8.7%, driven by increasing health awareness and higher disposable incomes.
Cosmos Health (NASDAQ:COSM) ha siglato un accordo di distribuzione con Scientific Pharmacy LLC per i suoi integratori alimentari Sky Premium Life in Oman. L'intesa prevede un ordine iniziale di 42.000 unità e rappresenta l'ingresso strategico di COSM nel mercato nutraceutico del GCC, valutato 6,91 miliardi di dollari nel 2024.
Scientific Pharmacy, controllata da Gulf Pharmaceutical Industries (Julphar), si occuperà di conformità regolatoria, registrazione dei prodotti, distribuzione, marketing e vendite al dettaglio attraverso la sua rete consolidata. Si prevede che il mercato nutraceutico del GCC raggiungerà 15,5 miliardi di dollari entro il 2033, con un tasso di crescita annuo composto (CAGR) dell'8,7%, trainato da una maggiore consapevolezza della salute e da redditi disponibili più elevati.
Cosmos Health (NASDAQ:COSM) ha firmado un acuerdo de distribución con Scientific Pharmacy LLC para sus suplementos alimenticios Sky Premium Life en Omán. El acuerdo incluye un pedido inicial de 42.000 unidades y marca la entrada estratégica de COSM en el mercado nutracéutico del GCC, valorado en 6,91 mil millones de dólares en 2024.
Scientific Pharmacy, propiedad de Gulf Pharmaceutical Industries (Julphar), se encargará del cumplimiento regulatorio, el registro de productos, la distribución, el marketing y las ventas al por menor a través de su red consolidada. Se proyecta que el mercado nutracéutico del GCC alcanzará los 15,5 mil millones de dólares para 2033, con un crecimiento anual compuesto (CAGR) del 8,7%, impulsado por una mayor concienciación sobre la salud y mayores ingresos disponibles.
Cosmos Health (NASDAQ:COSM)는 오만에서 자사 건강보조식품 Sky Premium Life의 유통을 위해 Scientific Pharmacy LLC와 유통계약을 체결했습니다. 이번 계약에는 초도 발주 42,000개가 포함되며, 이는 COSM의 GCC 영양보조제 시장(2024년 기준 69.1억 달러)에 대한 전략적 진입을 의미합니다.
Gulf Pharmaceutical Industries(줄파르)가 소유한 Scientific Pharmacy는 규제 준수, 제품 등록, 유통, 마케팅 및 소매 판매를 자사의 확립된 네트워크를 통해 담당합니다. GCC 영양보조제 시장은 건강 인식 증가와 가처분소득 상승에 힘입어 연평균 복합성장률(CAGR) 8.7%로 성장하여 2033년에는 155억 달러에 이를 것으로 전망됩니다.
Cosmos Health (NASDAQ:COSM) a signé un accord de distribution avec Scientific Pharmacy LLC pour ses compléments alimentaires Sky Premium Life en Oman. L'accord comprend une commande initiale de 42 000 unités et marque l'entrée stratégique de COSM sur le marché nutraceutique du GCC, estimé à 6,91 milliards de dollars en 2024.
Scientific Pharmacy, détenue par Gulf Pharmaceutical Industries (Julphar), prendra en charge la conformité réglementaire, l'enregistrement des produits, la distribution, le marketing et la vente au détail via son réseau établi. Le marché nutraceutique du GCC devrait atteindre 15,5 milliards de dollars d'ici 2033, avec un taux de croissance annuel composé (CAGR) de 8,7 %, porté par une sensibilisation accrue à la santé et des revenus disponibles plus élevés.
Cosmos Health (NASDAQ:COSM) hat einen Distributionsvertrag mit Scientific Pharmacy LLC für seine Nahrungsergänzungsmittel Sky Premium Life in Oman unterzeichnet. Der Vertrag umfasst eine erste Bestellung von 42.000 Einheiten und markiert COSMs strategischen Eintritt in den nutraceuticals-Markt des GCC, der im Jahr 2024 auf 6,91 Milliarden US-Dollar geschätzt wird.
Scientific Pharmacy, im Besitz von Gulf Pharmaceutical Industries (Julphar), übernimmt die regulatorische Compliance, Produktregistrierung, Distribution, das Marketing und den Einzelvertrieb über ihr etabliertes Netzwerk. Der GCC-Nutraceuticals-Markt wird voraussichtlich bis 2033 auf 15,5 Milliarden US-Dollar anwachsen, mit einer jährlichen Wachstumsrate (CAGR) von 8,7 %, angetrieben von steigendem Gesundheitsbewusstsein und höherem verfügbarem Einkommen.
- Strategic entry into the $6.91B GCC nutraceuticals market with significant growth potential
- Secured initial purchase order of 42,000 units from Scientific Pharmacy
- Partnership with established distributor owned by major pharmaceutical company with $350M annual revenue
- Target market expected to reach $15.5B by 2033 with 8.7% CAGR
- Market penetration and brand establishment may require significant time and resources
- Faces competition in a rapidly growing market with established players
Insights
Cosmos Health expands into Oman's nutraceutical market with a 42,000-unit order, leveraging Scientific Pharmacy's established distribution network.
Cosmos Health's expansion into Oman through its subsidiary Sky Pharm represents a strategic entry into the Gulf Cooperation Council (GCC) region's
The initial purchase order of 42,000 units provides Cosmos with immediate revenue generation while establishing a foothold in a market projected to grow at a
The agreement's comprehensive nature—covering distribution, marketing, logistics, and retail sales—gives Cosmos access to established channels without the capital expenditure typically required for independent market entry. The rapid growth trajectory of the GCC nutraceuticals market (projected to reach
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Sky Pharm SA, signed a distribution agreement (the “Agreement”) with Scientific Pharmacy LLC (“Scientific Pharmacy”) for its Sky Premium Life food supplement products in Oman.
Scientific Pharmacy, the retail and wholesale arm of Planet Pharmacies in Oman, is a leading healthcare and beauty company offering integrated distribution and retail services. Known for its international brand partnerships and strong customer focus, it has become a trusted name in Oman and continues to expand across the Gulf Cooperation Council (GCC) region. Planet Pharmacies is owned by Gulf Pharmaceutical Industries (Julphar), based in the United Arab Emirates, which is one of the largest pharmaceutical manufacturers in the Middle East and Africa, with annual revenue of approximately
Under the Agreement, Scientific Pharmacy will manage all core activities, including regulatory compliance, product registration, distribution, marketing, logistics, and the retail sale of Sky Premium Life products across pharmacies and stores in Oman through its established retail and distribution network. The Agreement also includes an initial purchase order of 42,000 units.
According to IMARC Group, the GCC nutraceuticals market was valued at
Greg Siokas, CEO of Cosmos Health, stated: “We are excited to announce our expansion into Oman, further strengthening our presence in the rapidly growing nutraceuticals market across the GCC. This milestone showcases the exceptional quality of our products and the increasing global demand for our Sky Premium Life brand. We expect the agreement to generate significant revenue for Cosmos, supported by Scientific Pharmacy’s established retail and distribution network and the rising demand for premium food supplements in Oman.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Such forward-looking statements include, but are not limited to, the Company’s expectation that accumulation of ETH will enhance long-term shareholder value through increasing ETH-per-share, the Company’s plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, that the Facility will provide access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and the Company’s planned entry into U.S. manufacturing and the anticipated use of proceeds. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
FAQ
What is the size of Cosmos Health's distribution agreement in Oman?
What is the current value of the GCC nutraceuticals market where COSM is expanding?
Who is Scientific Pharmacy and what will they do for COSM?
What is driving growth in the GCC nutraceuticals market where COSM is expanding?
How will this agreement impact Cosmos Health's revenue?
